One of the cornerstones of TAG’s work is weighing in on mission-related issues by sending comment letters to a variety of organizations, including Federal agencies, Senate and House committees, Pharmaceutical companies, and the WHO. Various staff members also frequently testify in person at committee hearings, and submit written testimony.
Letter to USPTO Opposing Gilead’s Patent Term Extension Request for TAG
January 31, 2020 — Treatment Action Group (TAG) joined 36 other organizations who signed on to this letter to the US Patent and Trademark Office (USPTO), opposing Gilead’s request for a patent term extension for tenofovir alafenamide (TAF). The letter also supports a recent petition submitted by PrEP4All, based on evidence that Gilead intentionally delayed development of TAF for approximately six years in order to maximize profits from another compound. TAG urges the USPTO to reject Gilead’s request and allow for greater access to TAF.
TAG Comment on the Trans-NIH Strategic Plan Goals for Sexual & Gender Minority (SGM) Health Research
January 24, 2020 — TAG submitted this public comment in response to a Request for Information on the Development of the Fiscal Year 2021-2025 Trans-NIH Strategic Plan for Sexual & Gender Minority Health Research, affirming the need for a research agenda that will best address HIV, TB, and HCV among LGBTQ+ communities and incorporate equity and justice in all such research.
Open Letter: Time to Lower the Price of Xpert Cartridges to $5
January 6, 2020 — TAG joined 156 organizations and individuals to demand that Cepheid lower the price of Xpert tests for TB, HIV, HCV and other diseases to improve access to rapid, accurate diagnostic testing.